Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity

British Journal of Dermatology

Volumn 146, Issue 3, 2002, Pages 399-408

  Miracco, C ^a   Margherita De Santi, M ^a   Schurfeld K ^a   Santopietro, R ^a   Lalinga, A V ^a   Fimiani, M ^a   Biagioli, M ^a   Brogi, M ^a   De Felice, C ^a   Luzi, P ^a   Andreassi, L ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

FISH; Melanocytic lesions; Telomerase activity; Telomeres

Indexed keywords

PARAFFIN; TELOMERASE;

ARTICLE; CHROMOSOME ANALYSIS; CHROMOSOME NUMBER; CHROMOSOME SIZE; CORRELATION ANALYSIS; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; IMAGING SYSTEM; MELANOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SKIN CARCINOMA; SKIN DEFECT; SKIN METASTASIS; TELOMERE;

CASE-CONTROL STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION, FLUORESCENCE; MELANOMA; NEOPLASM PROTEINS; NEVUS; NEVUS, PIGMENTED; SKIN NEOPLASMS; TELOMERASE; TELOMERE;

EID: 0036277964     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.04600.x     Document Type: Article

References (51)

1. Specific association of human telomerase activity with immortal cells and cancer
2. TIN2, a new regulator of telomere length in human cells
3. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2
4. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres
5. Control of telomere length by the human telomeric protein TRF1
6. The two-stage mechanism controlling cellular senescence and immortalization
7. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity
8. P53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis
9. Longevity, stress response, and cancer in aging telomerase-deficient mice
10. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
11. Telomere reduction in human colorectal carcinoma and with ageing
12. Length of telomeric repeats in neuroblastoma: Correlation with prognosis and other biological characteristics
13. Telomerase activity in human ovarian carcinoma
14. Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters
15. Telomeres and telomerase in human leukemias
16. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia
17. Telomerase activity and alterations in telomere length in human brain tumours
18. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span
19. Telomere length maintenance in aging and carcinogenesis
20. Analysis of telomerase and telomeres
21. Telomere length measurements using digital fluorescence microscopy
22. In situ analysis of changes in telomere size during replicative aging and cell transformation
23. Heterogeneity in telomere length of human chromosomes
24. Telomeres in the mouse have large interchromosomal variations in the number of T2AG3 repeats
25. Assessment of telomere length in hematopoietic interphase cells using in situ hybridization and digital fluorescence microscopy
26. Short telomeres on human chromosome 17p
27. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry
28. Reduction of telomeric signals in murine melanoma and human breast cancer lines treated with 3′-azido-2′-3′-dideoxythymidine
29. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis
30. Evaluation of telomerase activity in cutaneous melanocytic proliferations
31. Detection of telomerase activity and correlation with mitotic and apoptotic indices, Ki-67, and cyclin D1 and A expression in cutaneous melanoma
32. Possible diagnostic role of telomerase activity evaluation in the differential diagnosis between Spitz naevi and cutaneous malignant melanoma
33. Detection of telomerase activity in malignant and nonmalignant skin conditions
34. Telomerase activity, Ki-67, cyclin D1 and A expression, and apoptosis in solitary fibrous tumors: Additional features of a predictable course?
35. Telomere length dynamics in telomerase-positive immortal human cell populations
36. Genetic determination of telomere size in humans: A twin study of three age groups
37. Extension of life-span by introduction of telomerase into normal human cells
38. A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay
39. A survey of telomerase activity in human cancer
40. Detection of telomerase activity in skin, melanocytic naevi, and melanoma by telomerase PCR ELISA
41. Evidence for UV-associated activation of telomerase in human skin
42. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas
43. Telomerase activity in melanoma and non-melanoma skin cancer
44. Absence of telomerase activity and telomerase catalytic subunit mRNA in melanocyte cultures
45. Telomerase activity in melanocytic lesions: A potential marker of tumour biology
46. Quantification of fluorescence in situ hybridization signals by image cytometry
47. Rapid fluorescence in situ hybridization with repetitive DNA probes: Quantification by digital image analysis
48. In situ hybridization using synthetic oligomers as probes for centromere and telomere repeats
49. Staining of human telomeres with primed in situ labeling (PRINS)
50. Protein phosphatase 2a inhibits nuclear telomerase activity in human breast cancer cells
51. Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability